Edwards Lifesciences (EW) Stock Price, News & Analysis

Company Overview

Edwards Lifesciences Corporation is a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. Specializing in the design and manufacture of heart valves and transcatheter heart valve technologies, the company has established itself at the forefront of minimally invasive cardiac therapies. Its product offerings include surgical valve replacements, transcatheter heart valve systems, and an array of accessories designed to improve procedural efficiency and patient outcomes.

In its critical care segment, Edwards Lifesciences provides advanced hemodynamic monitoring solutions that deliver real-time insights into patient cardiovascular performance. The company’s HemoSphere advanced monitoring platform and Vigilance II monitor are widely used in operating rooms and intensive care units, helping clinicians make more informed decisions by continuously measuring key parameters such as cardiac output and systemic vascular resistance.

Founded in 1958 and headquartered in Irvine, California, Edwards Lifesciences serves patients and healthcare providers in over 100 countries. Its global footprint spans North America, Europe, Asia-Pacific, Latin America and the Middle East, supported by a network of direct sales teams, distributors and strategic partnerships. Through ongoing investments in research and development centers across multiple continents, the company drives innovation in both emerging and established markets.

Over the years, Edwards Lifesciences has grown through a combination of internal innovation and targeted acquisitions, building a portfolio that addresses a broad range of cardiovascular and critical care needs. Under the leadership of Chairman and Chief Executive Officer Michael A. Mussallem, the company remains committed to advancing patient care by developing next-generation therapies and monitoring technologies. Its governance structure includes a board of directors and executive team with deep expertise in medical technology, regulatory affairs and global commercialization.

Key Stats

• Today's Range: $77.21 to $78.33
• 50-Day Range: $73.31 to $78.34
• 52-Week Range: $58.93 to $95.25
• Volume: 1.86 million shs
• Average Volume: 5.23 million shs
• Market Capitalization: $45.89 billion
• P/E Ratio: 11.17
• Dividend Yield: N/A
• Price Target: $80.40
• Consensus Rating: Hold

Edwards Lifesciences Stock Analysis - MarketRank™

Edwards Lifesciences scored higher than 89% of companies evaluated by MarketBeat, and ranked 125th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Edwards Lifesciences has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 11 buy ratings, 13 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Edwards Lifesciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 12.24%

Earnings Growth

Earnings for Edwards Lifesciences are expected to grow by 12.24% in the coming year, from $2.45 to $2.75 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Edwards Lifesciences is 11.17, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.64.

Price to Earnings Ratio vs. Sector

The P/E ratio of Edwards Lifesciences is 11.17, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.20.

Price to Earnings Growth Ratio

Edwards Lifesciences has a PEG Ratio of 3.84. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Edwards Lifesciences has a P/B Ratio of 4.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.06% of the float of Edwards Lifesciences has been sold short.

Short Interest Ratio / Days to Cover

Edwards Lifesciences has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Edwards Lifesciences has recently increased by 3.94%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Edwards Lifesciences does not currently pay a dividend.

Dividend Growth

Edwards Lifesciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -0.95

Percentage of Shares Shorted

1.06% of the float of Edwards Lifesciences has been sold short.

Short Interest Ratio / Days to Cover

Edwards Lifesciences has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Edwards Lifesciences has recently increased by 3.94%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.34

News Sentiment

Edwards Lifesciences has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 26 news articles for Edwards Lifesciences this week, compared to 26 articles on an average week.

Search Interest

Only 14 people have searched for EW on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.

MarketBeat Follows

3 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,977,683.00 in company stock.

Percentage Held by Insiders

Only 1.29% of the stock of Edwards Lifesciences is held by insiders.

Percentage Held by Institutions

79.46% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EW Stock Analysis - Frequently Asked Questions

How have EW shares performed this year?

Edwards Lifesciences' stock was trading at $74.03 at the start of the year. Since then, EW stock has increased by 5.7% and is now trading at $78.23.

How were Edwards Lifesciences' earnings last quarter?

Edwards Lifesciences Corporation (NYSE:EW) issued its quarterly earnings results on Wednesday, April, 23rd. The medical research company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.60 by $0.04. Edwards Lifesciences's revenue for the quarter was up 6.2% compared to the same quarter last year.
Read the conference call transcript.

When did Edwards Lifesciences' stock split?

Edwards Lifesciences shares split on the morning of Friday, May 29th 2020.The 3-1 split was announced on Thursday, May 7th 2020. The newly issued shares were distributed to shareholders after the closing bell on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Does Edwards Lifesciences have any subsidiaries?

Edwards Lifesciences subsidiaries include these companies: CAS Medical Systems, Harpoon Medical, Valtech Cardio, CardiAQ Valve Technologies, BMEYE, Embrella Cardiovascular, Myocor, and others.

Who are Edwards Lifesciences' major shareholders?

Edwards Lifesciences' top institutional shareholders include Seilern Investment Management Ltd (0.21%), Swedbank AB (0.08%), Wealth Enhancement Advisory Services LLC (0.03%) and Czech National Bank (0.02%). Insiders that own company stock include Larry L Wood, Jean-Luc M Lemercier, Kieran Gallahue, Steven R Loranger, Bernard J Zovighian, Donald E Bobo Jr, Scott B Ullem, Catherine M Szyman, Daveen Chopra, Heisz Leslie Stone, Daniel J Lippis, Robert WA Sellers, Wayne Markowitz and Michael A Mussallem.
View institutional ownership trends.

How do I buy shares of Edwards Lifesciences?

Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Edwards Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Edwards Lifesciences investors own include Comcast (CMCSA), Chevron (CVX), Bristol Myers Squibb (BMY), Charles Schwab (SCHW), McKesson (MCK), Yum! Brands (YUM) and Toronto Dominion Bank (TD).

Company Calendar

• Last Earnings: 4/23/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 7/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Health Care Equipment
• Current Symbol: NYSE:EW
• CIK: 1099800
• Web: www.edwards.com
• Phone: (949) 250-2500
• Fax: 949-250-2525
• Employees: 15,800
• Year Founded: 1958

Price Target and Rating

• Average Price Target for Edwards Lifesciences: $80.40
• High Price Target: $95.00
• Low Price Target: $60.00
• Potential Upside/Downside: +3.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 25 Analysts

Profitability

• EPS (Trailing Twelve Months): $7.00
• Trailing P/E Ratio: 11.13
• Forward P/E Ratio: 31.81
• P/E Growth: 3.84
• Net Income: $4.17 billion
• Net Margins: 75.48%
• Pretax Margin: 29.08%
• Return on Equity: 16.62%
• Return on Assets: 12.64%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 4.45
• Quick Ratio: 3.66

Sales & Book Value

• Annual Sales: $5.44 billion
• Price / Sales: 8.40
• Cash Flow: $2.79 per share
• Price / Cash Flow: 27.98
• Book Value: $17.06 per share
• Price / Book: 4.57

Miscellaneous

• Outstanding Shares: 586,600,000
• Free Float: 579,033,000
• Market Cap: $45.71 billion
• Optionable: Optionable
• Beta: 1.11